Minlikeeva, AN;
Freudenheim, JL;
Eng, KH;
Cannioto, RA;
Friel, G;
Szender, JB;
Segal, B;
... Moysich, KB; + view all
(2017)
History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium.
Cancer Epidemiology Biomarkers & Prevention
, 26
(9)
pp. 1470-1473.
10.1158/1055-9965.EPI-17-0367.
Preview |
Text
Gentry-Maharaj_Cancer Epidemiol Biomarkers Prev.pdf - Accepted Version Download (281kB) | Preview |
Abstract
Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients. Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis, asthma, depression, osteoporosis, and autoimmune, gallbladder, kidney, liver and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled hazard ratios and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes. Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histological subtype, weight status, age at diagnosis or stage of disease (local/regional vs. advanced). Conclusions: Histories of endometriosis, asthma, depression, osteoporosis, and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival. Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis
| Type: | Article |
|---|---|
| Title: | History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1158/1055-9965.EPI-17-0367 |
| Publisher version: | http://doi.org/10.1158/1055-9965.EPI-17-0367 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1573924 |
Archive Staff Only
 |
View Item |
